FindMyKOL
Clinical trialNCT02349828WithdrawnPhase 2/3Interventional

Antiviral Prophylaxis in a Burn Population

NCT02349828 is a phase 2/3 interventional trial sponsored by Southern Illinois University. As of 21 Nov 2026, it was withdrawn. It studies Acyclovir in Herpes Simplex. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 30 Sept 2015 and a primary completion date of 30 Apr 2016.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02349828
FieldValue
Registry IDNCT02349828
StatusWithdrawn
PhasePhase 2/3
Study typeInterventional trial
Lead sponsorSouthern Illinois University
Enrollment0
Registered sites1
Countries1
ConditionsHerpes Simplex
DrugsAcyclovir
Start30 Sept 2015
Primary completion30 Apr 2016
Study completion30 Apr 2016
Last update posted21 Apr 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A prospective, randomized trial to calculate incidence of Herpes Simplex Virus in an in-patient burn population and determine efficacy of prophylactic antiviral therapy to prevent viral infection and/or reactivation. Hypothesis is that antiviral prophylaxis will be effective in reducing HSV infection/reactivation.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Michael W Neumeister, MD

    Southern Illinois Univeristy School of Medicine

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Illinois, United States1 site
  • Southern Illinois University School of Medicine

    Springfield

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 1 siteIL1IndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02349828

Each answer restates registry values shown on this page.

What is NCT02349828?

NCT02349828 is a phase 2/3 interventional trial sponsored by Southern Illinois University. It studies Acyclovir in Herpes Simplex.

Who leads NCT02349828?

The registry names Michael W Neumeister, MD (principal investigator, Southern Illinois Univeristy School of Medicine) as the overall official.

Where does NCT02349828 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02349828 study?

The registered drug and biological interventions are Acyclovir.

When did NCT02349828 end?

The registry lists a primary completion date of 30 Apr 2016 and a study completion date of 30 Apr 2016. The sponsor last updated the record on 21 Apr 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.